|
|
浅谈免疫检查点抑制剂联合放化疗治疗局限期小细胞肺癌的研究进展
|
Abstract:
局限期小细胞肺癌(LS-SCLC)是一种潜在的可治愈疾病。然而，大多数患者在最终治疗后不久出现疾病复发。一线铂/依托泊苷联合免疫疗法治疗大分期小细胞肺癌(SCLC)具有生存效益。因此，重要的是确定免疫治疗对总生存率的提高是否可以更早地转化为LS-SCLC的治疗模式。在这里，我们回顾了放射和免疫治疗联合的潜在临床前期，各自治疗方式的安全性和有效性，以及正在进行的探索LS-SCLC新治疗方法的试验。LS-SCLC的关键试验正在进行，预计将有助于了解免疫疗法与铂基放化疗并行治疗的有效性和安全性。
Limited stage small cell lung cancer (LS-SCLC) is a potentially curable disease. However, most pa-tients develop a disease relapse shortly after the definitive treatment. First-line plati-num/etoposide combined immunotherapy has survival benefits in treating large-stage small-cell lung cancer (SCLC). Therefore, it is important to determine whether the improved overall survival achieved by immunotherapy can translate earlier into treatment modalities for LS-SCLC. Here, we review the potential preclinical phase of the combination of radiation and immunotherapy, the safety and efficacy of the respective treatment modalities, and ongoing trials exploring new thera-pies for LS-SCLC. Key trials of LS-SCLC are ongoing and are expected to help understand the efficacy and safety of immunotherapy treated in parallel with platinum-based chemoradiotherapy.
| [1] | Ross, H.J., Hu, C., Higgins, K.A., Jabbour, S.K., Kozono, D.E., Owonikoko, T.K., et al. (2020) NRG Oncology/Alliance LU005: A Phase II/III Randomized Clinical Trial of Chemora-diation versus Chemoradiation plus Atezolizumab in Limited Stage Small Cell Lung Cancer. Journal of Clinical Oncology, 38, TPS9082. |
| [2] | Tachihara, M., Tsujino, K., Ishihara, T., Hayashi, H., Sato, Y., Kurata, T., Sugawara, S., Okamoto, I., Teraoka, S., Azuma, K., Daga, H., Yamaguchi, M., Kodaira, T., Satouchi, M., Shimokawa, M., Yamamoto, N., Nak-agawa, K. and Members of the West Japan Oncology Group (WJOG) (2021) Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Management and Research, 13, 9167-9173. https://doi.org/10.2147/cmar.s336262 |
| [3] | U.S. National Library of Medicine (2020) Efficacy and Safety of Standard of Care plus Durvalumab in Patients with Limited Disease Small Cell Lung Cancer (DOLPHIN). |
| [4] | Efficacy and Safety of SHR-1316 in Combination with Chemo-Radiotherapy in Patients with LS-SCLC.
https://clinicaltrials.gov/ct2/show/NCT04691063 |
| [5] | U.S. National Library of Medicine (2021) Durvalumab with Chemotherapy Followed By Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer. |
| [6] | Jagodinsky, J.C., Harari, P.M. and Morris, Z.S. (2020) The Promise of Combining Radiation Therapy with Immunotherapy. Interna-tional Journal of Radiation Oncology, Biology, Physics, 108, 6-16.
https://doi.org/10.1016/j.ijrobp.2020.04.023 |
| [7] | Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.D., Mauceri, H., Beckett, M., Darga, T., Huang, X., Gajewski, T.F., Chen, Z.J., Fu, Y.X. and Weichselbaum, R.R. (2014) STINGdependent Cytosolic DNA Sensing Promotes Radiationinduced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity, 41, 843-852. https://doi.org/10.1016/j.immuni.2014.10.019 |
| [8] | Rudin, C.M., Brambilla, E., Faivre-Finn, C. and Sage, J. (2021) Small-Cell Lung Cancer. Nature Reviews Disease Pri-mers, 7, Article No. 3. https://doi.org/10.1038/s41572-020-00235-0 |
| [9] | Waqar, S.N. and Morgensztern, D. (2017) Treatment Advances in Small Cell Lung Cancer (SCLC). Pharmacology & Therapeutics, 180, 16-23. https://doi.org/10.1016/j.pharmthera.2017.06.002 |
| [10] | Salem, A., Mistry, H., Hatton, M., Locke, I., Monnet, I., Blackhall, F. and Faivre-Finn, C. (2019) Association of Chemoradiotherapy with Outcomes Among Patients with Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology, 5, Arti-cle ID: e185335.
https://doi.org/10.1001/jamaoncol.2018.5335 |
| [11] | Simone II, C.B., Bogart, J.A., Cabrera, A.R., Daly, M.E., De-Nunzio, N.J., Detterbeck, F., et al. (2020) Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 10, 158-173. https://doi.org/10.1016/j.prro.2020.02.009 |
| [12] | Ganti, A.K.P., Loo, B.W., Bassetti, M., Blakely, C., Chiang, A., D’Amico, T.A., et al. (2021) Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19, 1441-1464. https://doi.org/10.6004/jnccn.2021.0058 |
| [13] | Faivre-Finn, C., Snee, M., Ashcroft, L., Appel, W., Barlesi, F., Bhatnagar, A., Bezjak, A., Cardenal, F., Fournel, P., Harden, S., Le Pechoux, C., McMenemin, R., Moham-med, N., O’Brien, M., Pantarotto, J., Surmont, V., Van Meerbeeck, J., Woll, P.J., Lorigan, P., et al. (2017) Concurrent Once-Daily versus Twice-Daily Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer (CONVERT): An Lung Cancer (TA Leal and N Sethakorn, Section Editors) Open-Label, Phase 3, Randomised, Superi-ority Trial. The Lancet Oncology, 18, 1116-1125.
https://doi.org/10.1016/S1470-2045(17)30318-2 |
| [14] | Steel, G.G. (1979) Terminology in the Description of Drugradiation Interactions. International Journal of Radiation Oncology, Biology, Physics, 5, 1145-1150. https://doi.org/10.1016/0360-3016(79)90634-5 |
| [15] | Donlon, N.E., Power, R., Hayes, C., Reynolds, J.V. and Lysaght, J. (2021) Radiotherapy, Immunotherapy, and the Tumour Microenvironment: Turning an Immunosuppressive Milieu into a Therapeutic Opportunity. Cancer Letters, 502, 84-96. https://doi.org/10.1016/j.canlet.2020.12.045 |
| [16] | Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S., et al. (2012) Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. New England Journal of Medicine, 366, 925-931.
https://doi.org/10.1056/NEJMoa1112824 |
| [17] | Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. (2015) Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer. Nature, 520, 373-377.
https://doi.org/10.1038/nature14292 |
| [18] | Hiniker, S.M., Reddy, S.A., Maecker, H.T., Subrahmanyam, P.B., Ros-enberg-Hasson, Y., Swetter, S.M., et al. (2016) A Prospective Clinical Trial Combining Radiation Therapy with System-ic Immunotherapy in Metastatic Melanoma. International Journal of Radiation Oncology, Biology, Physics, 96, 578-588.
https://doi.org/10.1016/j.ijrobp.2016.07.005 |
| [19] | Murphy, B., Walker, J., Bassale, S., Monaco, D., Jaboin, J.J., Ciporen, J., et al. (2017) Concurrent Radiosurgery and Immunotherapy Is Associated with Improved Intracranial Tumor Control in Patients with Metastatic Melanoma. International Journal of Radiation Oncology, Biology, Physics, 99, E523-E524.
https://doi.org/10.1016/j.ijrobp.2017.06.1857 |
| [20] | Arnett, A.L.H., Kottschade, L., Wilhite, T.J., Youland, R.S., Hocum, C., Whitaker, T.J., et al. (2017) Toxicity of Concurrent and Sequential PD-1 Immune Check Point Inhibitors with Conventional and Hypofractionated Radiation Therapy in Patients with Metastatic Disease. International Journal of Radiation Oncology, Biology, Physics, 99, E749.
https://doi.org/10.1016/j.ijrobp.2017.06.2402 |
| [21] | Jie, Y., Gu, A., Fu, P. and Kong, F.M.S. (2020) Does Radiation Increase the Risk of Immunotherapy Related Pneumonitis in Cancer Patients with Thorax Radiotherapy Combined Im-mune Checkpoint Inhibitors: A Meta-Analysis. Journal of Clinical Oncology, 38, e15099. https://doi.org/10.1200/JCO.2020.38.15_suppl.e15099 |
| [22] | Peters, S., Pujol, J.L., Dafni, U., Dómine, M., Popat, S., Reck, M., et al. (2022) Consolidation Nivolumab and Ipilimumab Versus Observation in Limited-Disease Small-Cell Lung Cancer after Chemo-Radiotherapy—Results from the Randomised Phase II ETOP/IFCT 4-12 STIMULI Trial. An-nals of Oncology, 33, 67-79.
https://doi.org/10.1016/j.annonc.2021.09.011 |
| [23] | Welsh, J.W., Heymach, J.V., Guo, C., Menon, H., Klein, K., Cushman, T.R., et al. (2020) Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Lim-ited-Stage SCLC. Journal of Thoracic Oncology, 15, 1919-1927. https://doi.org/10.1016/j.jtho.2020.08.022 |
| [24] | Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Cs？szi, T., Fül？p, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M.A., Lubiniecki, G.M, Shentu, Y., Rangwala, R., Brahmer, J.R. and KEYNOTE-024 Investigators (2016) Pembrolizumab versus Chem-otherapy for PD-L1-Positive Non-Small-Cell Lung Cancer Clinical Trial. New England Journal of Medicine, 375, 1823-1833. https://doi.org/10.1056/NEJMoa1606774 |
| [25] | U.S. National Library of Medicine (2018) Atezolizumab after Concurrent Chemo-Radiotherapy versus Chemo-Radiotherapy alone in Limited Disease Small-Cell Lung Can-cer. |
| [26] | U.S. National Library of Medicine (2018) Study of Durvalumab Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy. |
| [27] | Senan, S., Okamoto, I., Lee, G.W., Chen, Y., Niho, S., Mak, G., Yao, W., Shire, N., Jiang, H. and Cho, B.C. (2020) Design and Rationale for a Phase III, Randomized, Placebo-Controlled Trial of Durvalumab with or without Tremelimumab after Concurrent Chemoradiotherapy for Patients with Limited-Stage Small-Cell Lung Cancer: The ADRIATIC Study. Clinical Lung Cancer, 21, E84-E88. https://doi.org/10.1016/j.cllc.2019.12.006 |
| [28] | U.S. Na-tional Library of Medicine (2018) Chemoradiation with Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer. |
| [29] | Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., Wansley, E.K., Camphausen, K., Luiten, R.M., De Ru, A.H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F.A., Spits, H., Schlom, J., Van Veelen, P. and Neefjes, J.J. (2006) Radiation Modulates the Peptide Repertoire, Enhances MHC Class I Expression, and Induces Successful Antitumor Immunotherapy. Journal of Experimental Medi-cine, 203, 1259-1271.
https://doi.org/10.1084/jem.20052494 |
| [30] | U.S. National Library of Medicine (2019) Testing the Addition of a New Immu-notherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC). |
